centuri
herald
era
genom
medicin
map
human
genom
sequenc
advanc
field
genet
engin
transform
understand
gene
underpin
biolog
process
health
diseas
state
princip
brought
whole
genom
amen
sequencespecif
therapeut
intervent
via
nucleic
acid
base
molecul
concept
person
medicin
thu
becom
realiti
variou
genemanipul
technolog
antisens
methodolog
demonstr
proofofprincipl
treatment
rare
genet
diseas
howev
antisens
small
interf
rna
sirna
classic
antisens
oligonucleotid
aso
spliceswitch
aso
sso
microrna
mirna
antimirna
antagomir
gener
high
molecular
weight
highli
charg
entiti
thu
easili
travers
cell
membran
especi
case
neurodegen
disord
tightlyregul
bloodbrain
barrier
bbb
prevent
uptak
pharmaceut
hurdl
low
bioavail
poor
cellular
uptak
biolog
activ
nucleic
acid
mean
urgent
need
address
field
drug
deliveri
cellpenetr
peptid
cpp
also
known
protein
transduct
domain
could
one
solut
problem
comparison
extens
studi
tradit
deliveri
system
like
liposom
viral
vector
polymer
cationbas
system
polyplex
cpp
uniqu
short
fewer
amino
acid
cation
andor
amphipath
peptid
transloc
small
drugscargo
across
cell
membran
mani
earli
identifi
cpp
deriv
peptid
sequenc
found
natur
occur
protein
element
exhibit
inher
transloc
properti
import
subsequ
cpp
iter
includ
transactiv
transcript
hiv
hivtat
deriv
homeodomain
antennapedia
drosophila
transcript
factor
transportan
chimer
peptid
deriv
galanin
waspvenom
peptid
toxin
mastoparan
cation
polyarginin
polylysin
sequenc
sever
type
cargo
exampl
protein
nucleic
acid
base
macromolecul
sirna
plasmid
dna
aso
small
drug
molecul
transport
cpp
overcom
natur
cellular
biolog
barrier
led
increas
interest
util
cpp
deliveri
tool
genet
modifi
greatest
promis
demonstr
nucleic
acid
deliveri
organ
bodi
inher
poor
uptak
nake
deliveri
exampl
cpp
applic
list
tabl
review
intend
highlight
progress
cpp
develop
oligonucleotid
deliveri
could
expand
repertoir
novel
druggabl
target
within
context
cppmediat
deliveri
effector
nucleic
acid
either
directli
conjug
cpp
noncoval
complex
typic
form
nanoparticl
structur
figur
coval
conjug
occur
defin
structur
stoichiometri
predominantli
chargeneutr
oligonucleotid
chemistri
peptid
nucleic
acid
pna
phosphorodiamid
morpholino
pmo
cation
cpp
cpp
residu
long
join
coval
cargo
antisens
nucleic
acid
travers
biolog
membran
variou
peptidemedi
uptak
mechan
neutralcharg
backbon
chemistri
ideal
cargo
charg
cpp
avoid
problem
electrostat
interact
subsequ
aggreg
occur
anion
chemistri
one
earliest
studi
demonstr
potenti
direct
cpp
conjug
addit
four
lysin
pna
sequenc
enhanc
spliceswitch
activ
gfp
report
mous
model
compar
nake
pmo
abil
cpp
enhanc
pna
activ
investig
across
rang
cpp
class
includ
transportan
oligoarginin
ptat
penetratin
kff
nl
luciferasebas
spliceswitch
assay
transportan
highest
efficaci
key
find
studi
presenc
serum
led
inhibit
activ
subset
cpp
may
partli
explain
rel
success
vivo
studi
cpppna
nevertheless
cpppna
util
preclin
studi
target
cmyc
sever
combin
immunodefici
proof
concept
potent
vivo
inhibitor
mirna
upregul
follow
lipopolysaccharid
induct
one
promis
neutralcharg
chemistri
pmo
consist
morpholin
ring
place
ribos
phosphorodiamid
linkag
place
phosphodiest
compound
act
primarili
steric
blockag
complementari
rna
sequenc
either
inhibit
protein
translat
modifi
premrna
splice
pmo
effici
enter
cell
strategi
cpp
conjug
util
improv
cellular
uptak
enhanc
antisens
activ
conjug
cpp
pmo
use
sever
method
includ
maleimid
linkag
disulfid
linkag
click
chemistri
amid
linkag
enhanc
pmo
pharmacokinet
profil
biodistribut
stabil
promis
result
date
argininerich
peptid
contain
aminohexano
acid
betaalanin
spacer
improv
deliveri
spliceswitch
oligonucleotid
sso
therapeut
purpos
approach
explor
extens
duchenn
muscular
dystrophi
dmd
affect
newborn
boy
caus
primarili
outoffram
delet
dmd
gene
result
loss
structur
muscl
protein
dystrophin
absenc
dystrophin
caus
progress
muscl
degener
result
loss
ambul
prematur
death
due
respiratori
cardiac
failur
target
premrna
splice
exonskip
approach
restor
mrna
read
frame
around
delet
produc
intern
delet
yet
still
function
protein
approach
use
success
nake
pmo
result
condit
approv
eteplirsen
pmo
target
exon
dmd
gene
howev
despit
safe
profil
drug
evid
dystrophin
product
limit
rel
low
treatment
efficaci
restor
dystrophin
averag
normal
level
follow
week
treatment
need
therefor
remain
effect
compound
improv
dystrophin
level
thu
function
benefit
approach
use
cpp
improv
pmo
deliveri
one
approach
first
demonstr
argininerich
bpeptid
bpmo
demonstr
approxim
wildtyp
dystrophin
level
follow
singl
mgkg
dose
concurr
partial
restor
cardiac
function
measur
follow
dobutaminemedi
stress
induct
improv
muscl
function
follow
intraven
system
administr
mdx
mous
model
dmd
compar
extrem
favor
nake
pmo
weekli
administr
pmo
mgkg
week
could
achiev
wildtyp
dystrophin
level
subsequ
util
fusion
peptid
bpeptid
muscletarget
peptid
identifi
phage
display
msp
abl
improv
activ
multipl
mgkg
dose
although
interestingli
studi
orient
peptid
fusion
relat
pmo
conjug
shown
import
factor
activ
bpmo
also
util
studi
canin
model
dmd
greater
recapitul
human
diseas
patholog
thu
repres
sterner
test
abil
cpppmo
effect
restor
dystrophin
express
intraven
administr
repeat
low
dose
mgkg
per
aso
bpmo
induc
bodywid
dystrophin
restor
approxim
wildtyp
level
includ
heart
amelior
cardiac
conduct
abnorm
observ
treatment
import
proofofprincipl
studi
demonstr
cpppmo
could
success
dystroph
muscl
environ
contain
addit
barrier
uptak
fibrosi
fat
deposit
bpmo
also
util
therapeut
strategi
target
myoton
dystrophi
type
ctg
expans
untransl
region
dystrophia
myotonicaprotein
kinas
dmpk
gene
result
pathogen
transcript
complex
rnabind
protein
muscleblindlik
result
widespread
aberr
splice
abnorm
system
administr
bpmo
target
repeat
element
block
sequestr
result
normal
nuclear
distribut
subsequ
correct
abnorm
rna
splice
includ
chlorid
channel
gene
primari
contributor
myotonia
group
recent
develop
cpp
class
call
pnapmo
intern
peptid
pip
compris
hydrophob
core
region
flank
side
argrich
domain
contain
aminohexano
x
b
spacer
singl
mgkg
dose
induc
wildtyp
dystrophin
level
bodywid
skelet
muscl
similar
bpmo
significantli
introduct
core
sequenc
confer
approxim
dystrophin
express
heart
absent
bpmo
dose
level
iter
core
design
name
seri
peptid
demonstr
variabl
level
activ
suggest
minim
core
sequenc
length
requir
maintain
activ
although
precis
sequenc
less
import
furthermor
util
investig
pharmacodynam
approach
includ
observ
approxim
wildtyp
dystrophin
protein
level
requir
protect
eccentr
contractioninduc
muscl
damag
well
paramet
minim
efficaci
dose
level
mainten
effect
novel
cpp
develop
muscl
target
includ
identifi
phage
display
perform
myoblast
conjug
pmo
result
wildtyp
dystrophin
level
follow
singl
system
administr
although
dose
level
higher
compar
efficaci
b
pip
cpp
one
biggest
challeng
nucleic
acid
therapeut
field
system
deliveri
central
nervou
system
cn
barrier
repres
formid
barrier
even
smallmolecul
drug
potenti
cpp
deliv
nucleic
acid
cargo
demonstr
studi
wherebi
system
administr
argininerich
cpp
conjug
fitclabel
pmo
cargo
result
wide
detect
uptak
area
brain
notabl
cerebellum
purkinj
cell
although
function
benefit
uptak
report
recent
cpppmo
explor
preclin
model
spinal
muscular
atrophi
sma
wherebi
mutat
gene
result
loss
surviv
motor
neuron
smn
protein
subsequ
sever
motor
development
delay
prematur
death
paralog
gene
also
encod
smn
protein
produc
low
level
due
sequenc
variant
result
exclus
exon
matur
transcript
turn
produc
truncat
nonfunct
protein
strategi
employ
methoxyethyl
sso
nusinersen
target
intron
silenc
element
promot
inclus
exon
gene
recent
clinic
approv
demonstr
signific
improv
motor
function
surviv
rate
infant
deliveri
cn
essenti
approach
achiev
clinic
intrathec
administr
whilst
toler
place
consider
burden
patient
clinician
system
administr
would
like
prefer
rout
may
also
benefit
restor
smn
level
tissu
outsid
cn
address
intraven
administr
sever
mous
model
sma
increas
mean
surviv
drastic
improv
neuromuscular
junction
morpholog
rescu
level
circul
insulin
like
growth
factor
lower
dose
compar
efficaci
observ
nake
pmo
notabl
sever
mous
model
necessit
deliveri
postnat
day
show
function
benefit
like
bbb
may
fulli
form
reflect
clinic
situat
therapeut
intervent
address
system
administr
phenotyp
unaffect
adult
mous
model
sma
perform
studi
demonstr
increas
correct
smn
transcript
brain
spinal
cord
approxim
increas
liver
skelet
muscl
subsequ
studi
use
adult
mous
model
explor
put
braintarget
motif
enhanc
pmo
deliveri
branch
chain
peptid
design
target
apolipoprotein
receptor
brapo
induc
increas
exon
inclus
spinal
cord
lesser
extent
brain
one
limit
posit
charg
cpp
conjug
negativelycharg
nucleic
acid
sirna
aso
result
electrostat
interact
selfaggreg
potenti
interfer
oligonucleotid
target
bind
attempt
address
phage
display
perform
identifi
noncharg
home
peptid
would
enhanc
deliveri
sso
mdx
mous
model
conjug
candid
peptid
lgaqsnf
increas
exon
skip
activ
approxim
skelet
cardiac
tissu
follow
subcutan
administr
protocol
although
notabl
increas
protein
restor
observ
well
modul
splice
correct
genet
defect
sso
util
destruct
exon
skip
wherebi
induct
outoffram
transcript
result
nonsensemedi
decay
subsequ
loss
protein
signific
knockdown
gene
express
henc
protein
level
would
requir
function
effect
current
nake
sso
deliveri
technolog
like
ineffici
vivo
thu
pmo
conjug
b
peptid
util
exemplar
studi
target
myostatin
neg
regul
skelet
muscl
growth
differenti
combin
dmd
exon
skip
complementari
strategi
dmd
combinatori
treatment
improv
function
measur
muscl
patholog
mdx
model
greater
extent
dystrophin
express
alon
demonstr
potenti
destruct
exon
skip
altern
wide
use
sirna
rnaseh
gene
knockdown
strategi
combinatori
approach
also
util
simultan
target
two
gene
use
singl
cpppmo
construct
addit
second
pmo
either
click
chemistri
disulfid
linker
allow
two
pmo
deliv
singl
cpp
similar
spliceswitch
activ
two
separ
cpppmo
potenti
offer
advantag
reduc
cpp
toxic
burden
cppaso
approach
also
develop
antibacteri
agent
review
aso
alon
poor
capabl
penetr
bacteri
cell
membran
exemplar
studi
intranas
administr
rxr
target
acpp
mous
acinetobact
pneumonia
model
show
increas
surviv
time
reduc
pulmonari
bacteri
level
compar
salin
control
noncoval
cpp
strategi
depend
format
nanoparticl
complex
due
electrostat
andor
hydrophob
interact
anion
oligonucleotid
predominantli
amphipath
peptid
consist
hydrophil
polar
domain
hydrophob
nonpolar
domain
amphipath
peptid
confer
either
due
sequencespecif
order
along
peptid
chain
hydrophob
hydrophil
residu
primari
peptid
conform
structur
peptid
confer
hydrophil
hydrophob
side
structur
secondari
peptid
one
earliest
report
primari
amphipath
cpp
aso
deliveri
mpg
peptid
contain
hydrophob
domain
deriv
fusion
sequenc
hiv
hydrophil
domain
deriv
nuclear
local
sequenc
tantigen
modifi
version
peptid
use
deliv
sirna
target
cell
cycl
regul
cyclin
xenograft
tumor
mous
model
molar
ratio
cargo
peptid
found
crucial
determin
efficaci
optim
efficaci
achiev
molar
ratio
produc
stabl
particl
diamet
nm
whilst
intratumor
administr
complex
induc
complet
inhibit
tumor
growth
mgkg
intraven
system
inject
mgkg
induc
decreas
tumor
growth
resolv
particl
function
cholesterol
moieti
suggest
improv
potenc
stabil
longer
circul
time
addit
moieti
induc
significantli
increas
mous
surviv
day
compar
cholesterolfre
formul
reduct
tumor
growth
mgkg
group
also
report
develop
secondari
amphipath
peptid
cadi
consist
aromat
tryptophan
trp
cation
arginin
residu
adopt
helic
conform
within
membran
expos
trp
group
favor
cellular
uptak
stabil
sirnatoserum
exposur
improv
cadi
molar
ratio
increas
indic
cadi
protect
sirna
within
nanoparticl
complex
potenc
complex
confirm
vitro
difficult
transfect
cell
line
howev
vivo
data
report
literatur
date
one
potenti
limit
vivo
develop
cpp
potenti
degrad
intracellular
extracellular
proteas
address
cadyk
peptid
modifi
retroinverso
peptid
wherebi
peptid
consist
damino
acid
revers
sequenc
natur
occur
lisoform
peptid
term
rick
retroinverso
cadyk
similar
sirnamedi
knockdown
efficaci
parent
cadyk
nanoparticl
advantag
improv
resist
enzymat
serum
degrad
sirna
cargo
anoth
approach
cppmediat
sirna
deliveri
develop
branch
histidinelysin
hk
polym
wherebi
histidin
compon
requir
buffer
lyse
endosom
cellular
releas
cargo
lysin
compon
import
electrostat
bind
nucleic
acid
util
noncoval
approach
hk
polym
contain
sirna
direct
import
role
tumor
angiogenesi
abl
effect
reduc
xenograft
tumor
size
approxim
follow
multipl
system
dose
sirna
complex
tumor
growth
overt
toxic
detect
hydrophob
also
confer
cpp
addit
stearic
acid
modif
one
wide
publish
success
exampl
pepfect
peptid
famili
peptid
initi
develop
addit
ntermin
stearic
acid
modif
transportan
term
pepfect
enhanc
spliceswitch
activ
aso
approxim
compar
unmodifi
peptid
luciferas
base
cell
assay
surprisingli
peptid
inact
rnaimedi
silenc
address
endosomotrop
modif
chemic
analogu
chloroquin
introduc
enhanc
endosom
releas
well
exhibit
enhanc
sirna
potenc
commerci
avail
reagent
vitro
sirna
complex
induc
potent
target
gene
knockdown
kidney
lung
liver
organ
follow
singl
dose
mgkg
appar
acut
toxic
iter
peptid
modif
sequenc
also
effect
multipl
nucleic
acid
cargo
vitro
interestingli
could
demonstr
could
retain
activ
dri
solid
formul
sever
month
perhap
surprisingli
lipidfunction
cpp
pepfect
other
could
noncoval
formul
otherwis
difficult
transfect
chargeneutr
pmo
induc
effect
spliceswitch
activ
vitro
although
could
replic
vivo
deliveri
number
approach
cpp
design
made
improv
select
celltyp
specif
deliveri
nucleic
acid
cargo
especi
sirna
monoclon
antibodi
fragment
aptam
home
peptid
small
molecul
employ
improv
cell
tissu
specif
target
gener
conjug
fuse
cation
cpp
improv
interact
anion
sirna
conjug
singl
chain
antibodi
cpp
use
highli
efficaci
sirna
deliveri
primari
human
cell
proof
target
demonstr
mice
protect
hiv
challeng
follow
system
administr
vif
tattarget
sirna
nanoparticl
prevent
viral
spread
replic
short
peptid
deriv
rabi
viru
glycoprotein
rvg
known
specif
bind
acetylcholin
receptor
neuron
cell
function
sirna
complex
addit
nine
arginin
residu
intraven
administr
sirna
complex
wildtyp
mice
abl
induc
approxim
reduct
cuzn
superoxid
dismutas
level
brain
spleen
liver
efficaci
peak
hour
return
normal
level
around
day
addit
approach
use
mous
model
fatal
flavivir
enceph
surviv
antivir
sirna
treat
mice
compar
control
peptidesirna
group
die
within
day
altern
cellspecif
target
design
activat
cpp
acpp
improv
uptak
specif
environment
condit
cpp
gener
hairpin
structur
consist
cation
neutral
anion
domain
connect
cleavabl
peptid
loop
limit
cellular
uptak
due
neutral
electrostat
interact
cell
howev
presenc
diseaseassoci
proteas
linker
loop
cleav
thu
activ
cation
domain
cpp
approach
demonstr
target
cargofre
cpp
xenograft
tumor
model
differ
cancer
site
uptak
mediat
matrix
metalloproteinas
cleaveag
cpp
linker
tumorstrom
interfac
anoth
report
acpp
strategi
creat
phsensit
linkag
hydrazin
catalyz
decreas
ph
condit
observ
tumor
tissu
addit
phsensit
acpp
liposom
sirna
carrier
improv
uptak
targetgen
silenc
vitro
reduc
ph
condit
although
optim
requir
potenc
high
origin
cpp
approach
yet
demonstr
vivo
knowledg
sensit
ph
also
exploit
fusogen
peptid
function
activ
conform
chang
low
ph
acid
endosom
lysosom
aid
cargo
releas
compart
earli
exampl
peptid
deriv
hemagglutinin
random
coil
structur
physiolog
ph
adopt
conform
within
acid
endosom
fuse
destabil
endosom
membran
recent
fusion
peptid
term
consist
synthet
influenza
virusderiv
fusogen
domain
cation
arginin
domain
could
induc
signific
targetgen
silenc
subsequ
decreas
cell
invas
oral
cancer
cell
model
tissuespecif
target
capabl
peptid
enhanc
combin
epiderm
growth
factor
receptor
target
peptid
util
vivo
administr
xenograft
oral
cancer
tumor
gene
knockdown
could
detect
dual
peptid
nanoparticl
alon
mechan
cellular
intern
cpp
without
cargo
broadli
defin
either
energyindepend
direct
penetr
energydepend
endocytosi
graphic
repres
figur
observ
earli
cpp
experi
uptak
similar
energi
deplet
condit
suggest
direct
transloc
negativelycharg
plasma
membran
occur
via
energyindepend
mechan
direct
transloc
thought
occur
primarili
membran
destabil
transient
pore
format
carpetlik
model
accumul
lytic
cpp
cell
surfac
primarili
electrostat
interact
form
local
carpet
lead
reorgan
lipid
membran
transient
hole
form
allow
addit
cpp
enter
contrast
barrelpor
model
describ
format
transmembran
channel
form
due
insert
amphipath
peptid
wherebi
hydrophob
surfac
interact
lipid
membran
whilst
hydrophil
surfac
face
inward
thu
form
aqueou
pore
altern
propos
model
direct
uptak
invert
micel
model
wherebi
cpp
interact
lipid
bilay
would
result
format
invert
micel
would
trap
peptid
hydrophil
core
interact
membran
would
caus
invers
process
releas
cpp
intracellular
compart
howev
key
subsequ
studi
suggest
earli
observ
direct
penetr
may
inde
artifact
cell
fixat
method
consequ
major
microscop
studi
cpp
local
conduct
live
cell
nevertheless
direct
transloc
entir
rule
exampl
cadi
cpp
complex
sirna
coloc
endosom
marker
activ
presenc
endocyt
inhibitor
sinc
earli
studi
number
energi
depend
endocyt
pathway
includ
micropinocytosi
clathrin
caveolaemedi
endocytosi
sinc
identifi
primari
driver
cpp
without
nucleic
acid
cargo
review
comparison
sever
cation
amphipath
cpp
conjug
pna
result
suggest
cation
conjug
reli
micropinocytosi
whilst
amphipath
conjug
util
clathrinmedi
endocytosi
howev
endocyt
pathway
cpp
class
may
clearli
defin
larg
bodi
inform
suggest
specif
endocyt
pathway
util
cpp
highli
depend
properti
cargo
rel
concentr
cell
linetissu
target
clear
exampl
wherebi
caveolaemedi
endocytosi
primarili
respons
uptak
skelet
muscl
cell
clathrinmedi
endocytosi
import
cardiomyocyt
uptak
recent
cellsurfac
proteoglycan
glycosaminoglycan
like
heparan
sulphat
cofactor
scaveng
receptor
sr
also
impli
uptak
mechan
cpp
nanoparticl
sr
larg
famili
pattern
recognit
receptor
highli
express
immun
cell
play
import
role
innat
immun
homeostasi
neg
charg
pepfect
complex
taken
hela
cell
class
srdepend
endocytosi
pathway
subsequ
studi
also
demonstr
amphipath
cation
cpp
could
also
trigger
recruit
plasma
membran
sr
also
implic
uptak
spontan
form
amphipath
cpppmo
micel
sr
knockout
model
significantli
reduc
spliceswitch
activ
diaphragm
heart
tissu
compar
wildtyp
control
eleg
studi
understand
identifi
uptak
mechan
cpp
rna
express
profil
earli
cellular
respons
perform
hela
cell
transfect
without
oligonucleotid
cargo
ipa
analysi
suggest
autophagi
pathway
induc
upon
transfect
valid
ligand
modul
autophagi
coadminist
hela
luciferas
spliceswitch
report
system
modul
autophagyrel
intracellular
pathway
show
concentr
depend
effect
splice
correct
activ
furthermor
autophagi
induct
coloc
autophagosom
confirm
confoc
microscopi
transmiss
electron
microscopi
endocyt
uptak
cpp
cargo
follow
complex
intracellular
traffick
toward
earli
endosom
matur
late
endosomesmultivesicular
bodi
mvb
lysom
golgi
network
one
key
limit
factor
bioavail
cpp
cargo
enter
cell
pathway
endosom
entrap
research
activ
pursu
bioengin
method
fusogen
lipid
earli
escap
endosom
cytosol
prevent
destruct
thu
aid
deliveri
activ
site
cytoplasm
number
approach
focus
take
advantag
low
ph
environ
endosom
incorpor
phsensit
domain
cpp
use
destabil
lipid
membran
acid
ph
condit
endosom
aid
escap
similarli
histidin
moieti
act
proton
spong
endosom
ph
increas
osmot
pressur
lead
endosom
ruptur
cargo
releas
incorpor
lysomotrop
moieti
also
use
success
improv
endosom
escap
exemplifi
pepfect
incorpor
four
chloroquin
analog
improv
effici
cargo
deliveri
compar
parent
peptid
whilst
field
cppmediat
deliveri
oligonucleotid
expand
rapidli
within
last
year
success
clinic
trial
date
util
approach
larg
extent
reflect
field
moment
studi
focus
optim
cpp
design
gener
proof
principl
earli
preclin
studi
improv
cpp
design
coval
noncoval
applic
cpp
focus
predominantli
improv
cellular
uptak
although
tissuespecif
target
obviou
goal
approxim
uniqu
cpp
current
list
cppsite
databas
experiment
valid
repres
expens
timeconsum
studi
attempt
improv
upon
cpp
predict
differ
true
noncpp
form
basi
variou
machin
learn
model
predict
whether
novel
peptid
sequenc
cellpenetr
recent
exampl
includ
webbas
server
also
predict
uptak
effici
candid
cpp
sequenc
although
experiment
valid
alway
necessari
algorithm
may
improv
hitrat
broaden
design
landscap
outsid
major
cpp
famili
number
advantag
disadvantag
develop
coval
noncoval
approach
clinic
applic
cppaso
deliveri
coval
conjug
advantag
clearli
defin
entiti
produc
high
reproduc
gener
low
molar
ratio
cpptoaso
cargo
typic
import
consider
cpp
toxic
howev
product
compound
quit
labori
limit
predominantli
chargeneutr
oligonucleotid
backbon
turn
limit
biolog
applic
use
primarili
stericblock
approach
exonskip
process
noncoval
complex
due
electrostat
hydrophob
interact
cpp
aso
simplifi
usual
coincub
defin
concentr
also
advantag
approach
use
wider
rang
nucleic
acid
chemistri
well
type
effector
molecul
biolog
applic
rna
interfer
plasmid
dna
deliveri
howev
simplifi
complex
process
come
drawback
heterogen
nanoparticlelik
complex
form
potenti
aggreg
size
shape
charg
nanoparticl
crucial
uptak
efficaci
uniform
product
desir
consid
clinic
applic
assess
size
morpholog
pepfect
nickfect
nucleic
acid
nanoparticl
transmiss
electron
microscopi
demonstr
rel
homogen
popul
nanoparticl
rang
size
nm
produc
absenc
aggreg
suggest
least
peptid
rel
homogen
could
achiev
cpp
mediat
toxic
also
concern
approach
noncoval
approach
especi
typic
higher
molar
ratio
cpp
aso
requir
optim
efficaci
clinic
develop
safeti
toler
pharmacokinet
pharmacodynam
therapeut
index
major
factor
consid
nucleic
acid
deliveri
unfortun
vivo
assess
cppaso
toxicolog
robustli
report
although
assess
serum
marker
liver
damag
efficaci
dose
cpppmo
indic
hepat
toxic
least
argininebas
cpp
one
potenti
advantag
cppbase
approach
viralbas
deliveri
opportun
readministr
possibl
viral
vector
elicit
strong
immun
respons
upon
subsequ
administr
patient
preexist
viral
exposur
multipl
preclin
studi
cppaso
toler
multipledos
regimen
report
pepfect
mediat
deliveri
sirna
acut
inflammatori
cytokin
respons
could
detect
increas
serum
marker
kidney
liver
damag
observ
follow
intraven
deliveri
furthermor
addit
tat
antennapedia
transportan
cpp
epitheli
cell
concentr
effect
cargo
uptak
elicit
tolllik
receptor
signal
inflammatori
cytokin
clearest
insight
cppaso
toxic
administr
high
dose
bpeptidepmo
rat
demonstr
decreas
bodi
weight
elev
serum
blood
urea
nitrogen
creatinin
dosedepend
manner
suggest
reduc
renal
output
administr
high
dose
mgkg
also
accompani
mild
lethargi
immedi
postadministr
howev
note
respons
observ
dose
significantli
higher
minim
effect
dose
clinic
develop
program
avibiopharma
sarepta
therapeut
nonhuman
primat
administ
onceweekli
iv
administr
week
mgkg
rxrrbr
peptid
conjug
pmo
demonstr
averag
exon
skip
diaphragm
quadricep
heart
respect
howev
dose
mild
tubular
degener
detect
kidney
develop
compound
drop
howev
recent
investor
present
sarepta
shown
data
nonhuman
primat
studi
novel
cpppmo
target
exon
dmd
well
toler
show
efficaci
exonskip
activ
led
accept
investig
new
drug
applic
phase
trial
current
underway
estim
complet
earli
clinicaltrialsgov
field
cpp
deliveri
oligonucleotid
clearli
show
promis
evidenc
number
success
preclin
studi
wide
rang
diseas
indic
arisen
last
decad
greatest
success
like
come
target
organ
refractori
system
nake
oligonucleotid
deliveri
central
nervou
system
heart
skelet
muscl
need
effect
deliveri
paramount
realiz
power
specif
gene
diseas
mutat
target
oligonucleotid
offer
advanc
design
algorithm
better
understand
uptak
mechan
intracellular
traffick
therapeut
potenti
field
improv
like
see
cppaso
candid
move
toward
clinic
drug
develop
